Diabetic Nephropathy Market Size, Share & Industry Analysis, By Drug Class (Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers, Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors, Mineralocorticoid Receptor Antagonists, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Others), and Regional Forecast, 2024-2032

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate 

CAGR of 4.5% from 2024-2032

Unit

Value (USD Billion)

Segmentation

By Drug Class

• Angiotensin Converting Enzyme (ACE) Inhibitors


• Angiotensin Receptor Blockers


• Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors


• Mineralocorticoid Receptor Antagonists


• Others

By Distribution Channel

• Hospital Pharmacies


• Drug Stores & Retail Pharmacies


• Others

By  Geography

• North America (By Drug Class, By Distribution Channel, and By Country)
  
  
  
  • U.S.
  
  
  • Canada
  
  
  
  


• Europe (By Drug Class, By Distribution Channel, and By Country/Sub-region)
  
  
  
  • U.K.
  
  
  • Germany
  
  
  • France
  
  
  • Italy
  
  
  • Spain
  
  
  • Scandinavia
  
  
  • Rest of Europe
  
  
  
  


• Asia Pacific (By Drug Class, By Distribution Channel, and By Country/Sub-region)
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • Southeast Asia
  
  
  • Rest of Asia Pacific
  
  
  
  


• Rest of the World (By Drug Class, and By Distribution Channel)